Edgewise Therapeutics Inc [EWTX] stock is trading at $13.45, up 3.22%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EWTX shares have gain 16.25% over the last week, with a monthly amount drifted -45.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on April 02, 2025, when Scotiabank downgraded its rating to a Sector Perform but kept the price target unchanged to $14 for it. Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 07, 2025, and set its price target to $50. On January 22, 2025, Stifel initiated with a Hold rating and assigned a price target of $30 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating and suggested a price target of $45 on November 22, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $48 as its price target on March 07, 2024. In a note dated August 25, 2022, Goldman downgraded an Sell rating on this stock but restated the target price of $5.
Edgewise Therapeutics Inc [EWTX] stock has fluctuated between $10.60 and $38.12 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $13.45 at the most recent close of the market. An investor can expect a potential return of 271.75% based on the average EWTX price forecast.
Analyzing the EWTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.27 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.85 points at the first support level, and at 12.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.81, and for the 2nd resistance point, it is at 14.18.
Ratios To Look Out For
For context, Edgewise Therapeutics Inc’s Current Ratio is 19.93. In addition, the Quick Ratio stands at 19.93 and the Cash Ratio stands at 1.75.
Transactions by insiders
Recent insider trading involved Thompson Peter A., Director, that happened on Apr 03 ’25 when 0.5 million shares were purchased. Director, ORBIMED ADVISORS LLC completed a deal on Apr 03 ’25 to buy 0.5 million shares. Meanwhile, Chief Scientific Officer Russell Alan J sold 200.0 shares on Mar 07 ’25.
